ホーム > ブログ> Pharmaceutical industry is fiercely competitive Jiangsu pharmaceutical giants invest heavily in Beijing

Pharmaceutical industry is fiercely competitive Jiangsu pharmaceutical giants invest heavily in Beijing

August 17, 2023

Yangzijiang Pharmaceuticals, one of the top three in the domestic biopharmaceutical industry, took a huge amount of RMB 250 million to enter the “Zhongguancun” Beijing, a key scientific research center, yesterday, and compared with the Zhongguancun Life Science Park, which used to pick up the banner of the word “Ke” in the capital market. Signing contract - The target is locked in the research and development of modernization of Chinese medicine and biopharmaceutical industry.

pharmaceutical intermediate

The reporter interviewed Liu Liangming, director of the Propaganda Department of the Yangzijiang Pharmaceutical Group, at the first time after the signing of the two major companies yesterday. Liu Liangming told reporters that the current domestic pharmaceutical market is particularly fierce competition, the world's leading pharmaceutical giants are basically buried in China heavily. With a total assets of more than 2 billion yuan and sales revenue of nearly 3 billion yuan, Yangzijiang Pharmaceuticals is a company with a history of only 30 years, and these are the old international giants with a history and a net worth of more than 5 billion U.S. dollars. There is still a certain distance to strength. "But because of this, the strong desire of Yangzijiang Pharmaceuticals is particularly prominent." He pointed out that Yangzijiang Pharmaceutical is currently the world's leading Chinese medicine product, but the speed with which traditional Chinese medicines go to the world and many other Western medicine influxes into China is still relatively high. It is slower.
Jiangsu Yangzijiang Pharmaceutical Group is a national large-scale pharmaceutical enterprise group supported by high technology. The 10,000-ton extraction building with annual extraction of medicinal herbs is currently the largest domestic extraction and production base for Chinese medicine in Asia and even Asia. Earlier, it had invested 600 million yuan to start construction of four R&D centers in Nanjing, Shanghai and Sichuan. The purpose of this cooperation with Zhongguancun, what exactly do you want? Liu told reporters that the company currently has more than 1800 R & D personnel, but relatively few top-level talents, because the company headquarters in Taizhou, many top scientific research personnel do not want to "down" "This selection of Zhongguancun is mainly based on its scientific and technological strength and its smooth information advantage. The research and development center was selected in Beijing's Zhongguancun. It is also due to the consideration of talented people."
お問い合わせ

Author:

Mr. fengyi

Eメール:

chemtarget@gmail.com

Phone/WhatsApp:

+8613548425599

人気商品
You may also like
Related Categories

この仕入先にメール

タイトル:
イーメール:
メッセージ:

Your message must be betwwen 20-8000 characters

We will contact you immediately

Fill in more information so that we can get in touch with you faster

Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.

送信